Activin Receptors, Type I
"Activin Receptors, Type I" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
One of the two types of ACTIVIN RECEPTORS or activin receptor-like kinases (ALK'S). There are several type I activin receptors. The major active ones are ALK-2 (ActR-IA) and ALK-4 (ActR-IB).
MeSH Number(s)
D08.811.913.696.620.682.700.062.500
D12.776.543.750.750.400.820.500.500
Below are MeSH descriptors whose meaning is more general than "Activin Receptors, Type I".
Below are MeSH descriptors whose meaning is more specific than "Activin Receptors, Type I".
This graph shows the total number of publications written about "Activin Receptors, Type I" by people in Harvard Catalyst Profiles by year, and whether "Activin Receptors, Type I" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1996 | 2 | 0 | 2 |
1997 | 2 | 0 | 2 |
1998 | 0 | 1 | 1 |
1999 | 2 | 2 | 4 |
2000 | 1 | 2 | 3 |
2001 | 1 | 2 | 3 |
2002 | 1 | 1 | 2 |
2003 | 0 | 3 | 3 |
2004 | 1 | 2 | 3 |
2005 | 2 | 0 | 2 |
2006 | 1 | 3 | 4 |
2007 | 0 | 1 | 1 |
2008 | 2 | 2 | 4 |
2009 | 0 | 4 | 4 |
2010 | 1 | 0 | 1 |
2011 | 2 | 1 | 3 |
2012 | 1 | 2 | 3 |
2013 | 2 | 2 | 4 |
2014 | 4 | 0 | 4 |
2015 | 1 | 2 | 3 |
2016 | 2 | 4 | 6 |
2017 | 3 | 6 | 9 |
2018 | 3 | 1 | 4 |
2019 | 3 | 0 | 3 |
2020 | 2 | 1 | 3 |
2021 | 2 | 2 | 4 |
2022 | 0 | 2 | 2 |
2023 | 0 | 1 | 1 |
Below are the most recent publications written about "Activin Receptors, Type I" by people in Profiles.
-
Multifocal heterotopic ossification in a man with germline variants of LIM Mineralization Protein-1 (LMP-1). Am J Med Genet A. 2023 08; 191(8):2164-2174.
-
Integrated longitudinal analysis of adult grade 4 diffuse gliomas with long-term relapse interval revealed upregulation of TGF-ß signaling in recurrent tumors. Neuro Oncol. 2023 04 06; 25(4):662-673.
-
Rare loss of function variants in the hepatokine gene INHBE protect from abdominal obesity. Nat Commun. 2022 07 27; 13(1):4319.
-
Anti-ACVR1 antibodies exacerbate heterotopic ossification in fibrodysplasia ossificans progressiva (FOP) by activating FOP-mutant ACVR1. J Clin Invest. 2022 06 15; 132(12).
-
Generation of an induced pluripotent stem cell line (TRNDi012-B) from Fibrodysplasia Ossificans Progressiva (FOP) patient carrying a heterozygous mutation c. 617G > A in the ACVR1 gene. Stem Cell Res. 2021 07; 54:102424.
-
Saracatinib is an efficacious clinical candidate for fibrodysplasia ossificans progressiva. JCI Insight. 2021 04 22; 6(8).
-
ActRIIB:ALK4-Fc alleviates muscle dysfunction and comorbidities in murine models of neuromuscular disorders. J Clin Invest. 2021 02 15; 131(4).
-
Suppressed prefrontal cortex oscillations associate with clinical pain in fibrodysplasia ossificans progressiva. Orphanet J Rare Dis. 2021 01 30; 16(1):54.
-
Leveraging an Open Science Drug Discovery Model to Develop CNS-Penetrant ALK2 Inhibitors for the Treatment of Diffuse Intrinsic Pontine Glioma. J Med Chem. 2020 09 10; 63(17):10061-10085.
-
Activin A does not drive post-traumatic heterotopic ossification. Bone. 2020 09; 138:115473.